GLAXF - GSK: Robust Earnings Report Expected 2024 Outlook Is Key

2024-01-26 17:56:59 ET

Summary

• GSK's Q4 2023 and full-year 2023 earnings released later this month are expected to continue showing strength, especially with the successful launch of Arexvy, its respiratory disease vaccine.
• However, there are risks ahead too, as Zantac hearings are now underway and initial assessments of the company's earnings in 2024 are underwhelming.
• Still, much depends on the company's own outlook. In the meantime, its market multiples aren't high and it's dividend yield isn't bad either.

Since I last wrote an earnings preview on pharmaceuticals company GSK ( NYSE:GSK ) last October, its price is up by 11.8%, which was to be expected on good results and the settlement of its heartburn medication, Zantac, related cases in California. ...

For further details see: